CN111732629B - 一种寡肽、减肥组合物及制备方法和应用 - Google Patents
一种寡肽、减肥组合物及制备方法和应用 Download PDFInfo
- Publication number
- CN111732629B CN111732629B CN202010571191.2A CN202010571191A CN111732629B CN 111732629 B CN111732629 B CN 111732629B CN 202010571191 A CN202010571191 A CN 202010571191A CN 111732629 B CN111732629 B CN 111732629B
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- weight
- composition
- reducing
- pancreatic lipase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 83
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 102000019280 Pancreatic lipases Human genes 0.000 claims abstract description 35
- 108050006759 Pancreatic lipases Proteins 0.000 claims abstract description 35
- 229940116369 pancreatic lipase Drugs 0.000 claims abstract description 35
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 235000019626 lipase activity Nutrition 0.000 claims abstract description 3
- 241000229143 Hippophae Species 0.000 claims description 27
- 235000003935 Hippophae Nutrition 0.000 claims description 21
- 210000000582 semen Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 230000004580 weight loss Effects 0.000 claims description 10
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003729 cation exchange resin Substances 0.000 claims description 8
- 108010019160 Pancreatin Proteins 0.000 claims description 7
- 230000000415 inactivating effect Effects 0.000 claims description 7
- 229940055695 pancreatin Drugs 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 230000002411 adverse Effects 0.000 abstract description 2
- 239000007864 aqueous solution Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 20
- 238000004108 freeze drying Methods 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108010009736 Protein Hydrolysates Proteins 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000003531 protein hydrolysate Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 7
- 239000005642 Oleic acid Substances 0.000 description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108090000145 Bacillolysin Proteins 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 102000035092 Neutral proteases Human genes 0.000 description 6
- 108091005507 Neutral proteases Proteins 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 239000004006 olive oil Substances 0.000 description 6
- 208000016261 weight loss Diseases 0.000 description 6
- 235000008721 Terminalia amazonia Nutrition 0.000 description 5
- 241001263290 Terminalia amazonia Species 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002173 cutting fluid Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000727169 Prinsepia utilis Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Botany (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了一种寡肽、减肥组合物及制备方法和应用。其中,所述寡肽具有如下的氨基酸序列:Ala‑Pro‑Tyr‑Arg。该寡肽具有抑制胰脂肪酶活性的效果,且天然、安全、无毒副作用、可长期服用。
Description
技术领域
本发明涉及生物技术领域,具体涉及一种寡肽、减肥组合物及制备方法和应用。
背景技术
随着人们物质生活的不断提高,不健康的高脂饮食和不良生活习惯诱发多种慢性疾病的发生。脂质的过多摄入和运动的严重缺乏,导致脂肪沉积在身体各个部位,逐渐演变成肥胖症。肥胖与许多慢性疾病有关,如糖尿病、脂肪肝和心血管疾病等,食物中的脂肪需要经过胃肠道中相应的消化酶的水解后才能够被身体吸收,饮食中70%左右脂肪是由胰脂肪酶进行水解消化。因此,通过抑制胰脂肪酶的活性,降低和延缓餐后脂肪水解和吸收,从而可以有效缓解肥胖和高血脂等健康问题。
目前已有奥利司他等抑制脂肪酶的药物上市,但奥利司他有明显的副作用。因此,寻找天然、安全、无毒副作用、可长期服用的胰脂肪酶抑制剂类成为研究的热点。
虽然有报道从盐肤木果实提取物中提取得到的酚类物质具有胰脂肪酶抑制活性;以青刺果果皮和果肉为原料提取得到的黄酮类化合物具有胰脂肪酶抑制活性等,但是目前尚未见关于具有胰脂肪酶抑制活性的寡肽类化合物的报道。
发明内容
因此,本发明要提供一种通过控制沙棘蛋白的酶解制备具有胰脂肪酶抑制活性的寡肽化合物,具体的是提供一种寡肽、减肥组合物及制备方法和应用。
为此,本发明提供如下技术方案:
一种寡肽,具有如下的氨基酸序列:Ala-Pro-Tyr-Arg。
本发明还提供了一种减肥组合物,包含上述的寡肽。
进一步地,所述减肥组合物中寡肽的含量为0.4-2.5g/100g。
更进一步地,所述减肥组合物中寡肽的含量为1.0-1.9g/100g。
进一步地,所述减肥组合物位膳食补充剂。
本发明还提供了上述的减肥组合物的制备方法,包括如下步骤:
将沙棘籽粉碎后加水,调节pH为5.0-7.0,酶解,灭酶,取上清液,即得所述减肥组合物。
进一步地,酶解时采用胰酶或中性蛋白酶。
进一步地,所述粉碎后沙棘籽与酶的质量比为100:0.1-2.0。
进一步地,酶解的温度为25-60℃,时间为2-24h;
进一步地,取上清液之前还包括离心的步骤,所述离心的温度为3-5℃,时间为10-20min,转速为6000-10000rpm。
进一步地,还包括将上清液冷冻干燥的步骤。
粉碎后沙棘籽与水的质量比为1:(10-15)。
本发明还提供了上述寡肽的提纯方法,包括如下步骤:
将上述的减肥组合物或上述的减肥组合物的制备方法制得的减肥组合物依次经超滤、阳离子交换树脂,透析,色谱柱分离,即得所述寡肽。
进一步地,超滤时收集分子量小于3kDa的滤液。
进一步地,将上述的减肥组合物配置成0.1-0.2mg/mL的水溶液以0.1-1mL/min的速率经超滤膜过滤,并收集分子量小于3kDa的滤液。
进一步地,将超滤后的滤液干燥并配置成5-10mg/mL的水溶液并混入阳离子交换树脂,然后采用2-5wt%的氯化钠溶液以0.1-0.2mL/min的速率进行洗脱。
进一步地,将洗脱液采用透析膜透析后的溶液干燥,然后配置成5-10mg/mL的水溶液,采用色谱柱进行分离,洗脱条件为:体积含量为20-40%的乙醇洗脱,收集洗脱液,即得所述寡肽。
上述的洗脱速率以及洗脱液可根据实际情况进行调整。
本发明还提供了上述的寡肽或上述的寡肽的提纯方法提取的寡肽或上述的减肥组合物或上述述的减肥组合物的制备方法制得的减肥组合物在抑制胰脂肪酶活性中的应用。
本发明还提供了上述的寡肽或上述的寡肽的提纯方法提取的寡肽或上述的减肥组合物或上述述的减肥组合物的制备方法制得的减肥组合物在减肥类食品、药品或保健品的应用。
本发明提供的APYR寡肽在0.1-1mg/kg.d的剂量下,可显著抑制胰脂肪酶的活性。
本发明技术方案,具有如下优点:
1.本发明提供的寡肽,具有如下的氨基酸序列:Ala-Pro-Tyr-Arg。该寡肽具有抑制胰脂肪酶活性的效果,且天然、安全、无毒副作用、可长期服用。
2.本发明提供的减肥组合物,包含如下的氨基酸序列的寡肽:Ala-Pro-Tyr-Arg,该减肥组合物具有抑制胰脂肪酶活性的效果,且天然、安全、无毒副作用、可长期服用。
3.本发明提供的减肥组合物,其中寡肽的含量为0.4-2.5g/100g。通过限定其中寡肽的含量,可进一步提高抑制胰脂肪酶活性的效果。
4.本发明提供的减肥组合物,可用作膳食补充剂使用,且该膳食补充剂具有抑制胰脂肪酶活性的效果,天然、安全、无毒副作用、可长期服用。
5.本发明提供的减肥组合物的制备方法,包括如下步骤:将沙棘籽粉碎后加水,调节pH为5.0-7.0,酶解,灭酶,取上清液,即得所述减肥组合物。通过采用上述的方法,即可酶解得到含有Ala-Pro-Tyr-Arg氨基酸序列的寡肽的减肥组合物,该减肥组合物具有抑制胰脂肪酶活性的效果,而且天然、安全、无毒副作用、可长期服用。
6.本发明提供的减肥组合物的制备方法,通过限定酶解时采用的酶为胰酶或中性蛋白酶,可提高酶解得到的减肥组合物中Ala-Pro-Tyr-Arg寡肽的含量。
7.本发明提供的减肥组合物的制备方法,通过限定所述酶与粉碎后沙棘籽的质量比,可提高酶解效果及减肥组合物中寡肽的含量,进而提高其抑制胰脂肪酶活性的效果。
8.本发明提供的寡肽的提纯方法,通过依次将减肥组合物经超滤、阳离子交换树脂,透析,色谱柱分离,即得所述寡肽。如果调换顺序或者是是采用其他的例如阴离子交换树脂等,均不能分离得到所述寡肽。
9.本发明提供的寡肽的提纯方法,通过限定超滤时收集分子量小于3kDa的滤液,可提高分离得到的寡肽的纯度。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是本发明实施例1制得的减肥组合物中APYR寡肽的二级质谱图;
图2是本发明实验例2中APYR寡肽减肥组合物对胰脂肪酶抑制效率的双倒数图;
图3本发明实施例2制得的减肥组合物在不同pH下的胰脂肪酶抑制活性保留率。
具体实施方式
提供下述实施例是为了更好地进一步理解本发明,并不局限于所述最佳实施方式,不对本发明的内容和保护范围构成限制,任何人在本发明的启示下或是将本发明与其他现有技术的特征进行组合而得出的任何与本发明相同或相近似的产品,均落在本发明的保护范围之内。
实施例中未注明具体实验步骤或条件者,按照本领域内的文献所描述的常规实验步骤的操作或条件即可进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规试剂产品。
寡肽的结构鉴定均采用HPLC-MS/MS。
减肥组合物中寡肽含量的测定均采用高效液相色谱法(HPLC)。高效液相色谱的具体检测条件为:
流速:0.2mL/min;紫外检测波长:220nm;正离子模式,分子量选择50-3000;C18色谱柱;
实施例1
本实施例提供一种含Ala-Pro-Tyr-Arg(APYR)寡肽的减肥组合物,其制备方法如下:
将沙棘籽粉碎至100目后与水按照质量比为1:10混合得沙棘籽的水溶液,调节其pH至6.5后添加中性蛋白酶(中性蛋白酶与粉碎后沙棘籽的质量比为0.25:100),然后在37℃搅拌水解2h,水解结束后于95℃灭酶15min,得沙棘籽蛋白水解产物;
将上述沙棘籽蛋白水解产物在4℃,8000rpm离心20min,然后取上清液冷冻干燥,即得含APYR寡肽的减肥组合物。经HPLC检测,所述减肥组合物中APYR寡肽的含量为1.85g/100g。
本实施例还提供了Ala-Pro-Tyr-Arg(APYR)寡肽的一种提纯方法,包括如下步骤:
将上述的减肥组合物配置成0.1mg/mL的水溶液以0.6mL/min的速率经PLCGC超滤膜过滤,并收集分子量小于3kDa的滤液;然后冷冻干燥,得粉末1;
将固体粉末1配置成8mg/mL的水溶液并混入732阳离子交换树脂,然后采用3wt%的氯化钠溶液以0.2mL/min的速率进行洗脱,收集洗脱液;
将洗脱液采用分子量为10000的纤维素膜透析后的溶液冷冻干燥,得粉末2;
将粉末2配置成5mg/mL的水溶液,采用SEP-C18色谱小柱进行分离,洗脱条件为:体积含量为40%的乙醇洗脱,收集洗脱液,冷冻干燥,干燥后的物质经HPLC-MS/MS鉴定为具有如下氨基酸序列Ala-Pro-Tyr-Arg(APYR)的寡肽。如图1所示,具体的数值如下表1所示。
表1
一级质谱 | 二级离子碎片 | |
APYR | 527.3183 | 456.2829,359.2324,197.1315(Arg+Na<sup>+</sup>) |
实施例2
本实施例提供一种含Ala-Pro-Tyr-Arg(APYR)寡肽的减肥组合物,其制备方法如下:
将沙棘籽粉碎至100目后与水按照1:15的质量比混合得沙棘籽的水溶液,调节其pH至5.0后添加胰酶(胰酶与粉碎后沙棘籽的质量比为1.0:100),然后在25℃搅拌水解24h,水解结束后于85℃灭酶10min,得沙棘籽蛋白水解产物;
将上述沙棘籽蛋白水解产物在3℃,10000rpm离心10min,然后取上清液,冷冻干燥,即得含APYR寡肽的减肥组合物。经HPLC检测,所述减肥组合物中APYR寡肽的含量为1.18g/100g。
本实施例还提供了Ala-Pro-Tyr-Arg(APYR)寡肽的一种提纯方法,包括如下步骤:
将上述的减肥组合物配置成0.2mg/mL的水溶液以0.1mL/min的速率经PLCGC超滤膜过滤,并收集分子量小于3kDa的滤液;然后冷冻干燥,得粉末1;
将粉末1配置成5mg/mL的水溶液并混入732阳离子交换树脂,然后采用2wt%的氯化钠溶液以0.1mL/min的速率进行洗脱,收集洗脱液;
将洗脱液采用分子量为10000的纤维素膜透析后的溶液冷冻干燥,得粉末2;
将粉末2配置成10mg/mL的水溶液,采用SEP-C18色谱小柱进行分离,洗脱条件为:体积含量为20%的乙醇洗脱,收集洗脱液,冷冻干燥,干燥后的物质经HPLC-MS/MS鉴定,为具有如下氨基酸序列Ala-Pro-Tyr-Arg(APYR)的寡肽。
实施例3
本实施例提供一种含Ala-Pro-Tyr-Arg(APYR)寡肽的减肥组合物,其制备方法如下:
将沙棘籽粉碎至100目后与水按照质量比为1:12混合得沙棘籽的水溶液,调节其pH至7.0后添加胰酶(所述胰酶与粉碎后沙棘籽的质量比为2.0:100),然后在60℃搅拌水解15h,于90℃灭酶20min,得沙棘籽蛋白水解产物;
将上述沙棘籽蛋白水解产物在5℃,6000rpm离心15min,然后取上清液,冷冻干燥,即得含APYR寡肽的减肥组合物。经HPLC检测,所述减肥组合物中APYR寡肽的含量为1.02g/100g。
本实施例还提供了Ala-Pro-Tyr-Arg(APYR)寡肽的一种提纯方法,包括如下步骤:
将上述的减肥组合物配置成0.15mg/mL的水溶液以1mL/min的速率经PLCGC超滤膜过滤,并收集分子量小于3kDa的滤液;然后冷冻干燥,得粉末1;
将粉末1配置成10mg/mL的水溶液并混入732阳离子交换树脂,然后采用5wt%的氯化钠溶液以0.1mL/min的速率进行洗脱,收集洗脱液;
将洗脱液采用分子量为10000的纤维素膜透析后的溶液冷冻干燥,得粉末2;
将粉末2配置成8mg/mL的水溶液,采用SEP-C18色谱小柱进行分离,洗脱条件为:体积含量为30%的乙醇洗脱,收集洗脱液,冷冻干燥,干燥后的物质经HPLC-MS/MS鉴定,为具有如下氨基酸序列Ala-Pro-Tyr-Arg(APYR)的寡肽。
对比例1
本对比例提供一种减肥组合物,其制备方法如下:
将沙棘籽粉碎至100目后与水按照质量比为1:10混合得沙棘籽的水溶液,调节其pH至8.0后添加中性蛋白酶(中性蛋白酶与粉碎后沙棘籽的质量比为0.25:100),然后在37℃搅拌水解2h,水解结束后于95℃灭酶15min,得沙棘籽蛋白水解产物;
将上述沙棘籽蛋白水解产物在4℃,8000rpm离心20min,然后取上清液冷冻干燥,即得含APYR寡肽的减肥组合物。经HPLC检测,没有发现Ala-Pro-Tyr-Arg寡肽。
然后将上述的减肥组合物配置成0.1mg/mL的水溶液以0.6mL/min的速率经PLCGC超滤膜过滤,并收集分子量小于3kDa的滤液;然后冷冻干燥,得粉末1;
将固体粉末配置成8mg/mL的水溶液并混入732阳离子交换树脂,然后采用3wt%的氯化钠溶液以0.2mL/min的速率进行洗脱,收集洗脱液;
将洗脱液采用分子量为10000的纤维素膜透析后的溶液冷冻干燥,得粉末2;
将粉末2配置成5mg/mL的水溶液,采用SEP-C18色谱小柱进行分离,洗脱条件为:体积含量为40%的乙醇洗脱,收集洗脱液,冷冻干燥,干燥后的物质经HPLC-MS/MS鉴定,所述减肥组合物中不含有氨基酸序列为Ala-Pro-Tyr-Arg的寡肽。
实验例1
将各实施例制得的减肥组合物进行胰脂肪酶抑制率的测试,具体测试方法为:
白色橄榄油底物乳化液的制备:称取聚乙烯醇20g与800g水混合加热至全部溶解,然后用纱布过滤后,取150mL的滤液与50mL的橄榄油混合,均质10min,即得白色橄榄油底物乳化液。
向25mL比色管中分别加入2mL上述白色橄榄油底物乳化液及2.5mL的磷酸缓冲盐溶液PBS(0.005M,pH为7.5),漩涡震荡混匀后于恒温水浴锅(40℃)预热5min,再分别加入1mL减肥组合物(1mg/mL)和0.5mL胰脂肪酶溶液(3mg/mL)充分混合,于恒温水浴(40℃)中准确反应20min(间隔摇晃10次)后,迅速加入6mL95%乙醇和1mL 6M盐酸中止反应,再加入3mL异辛烷漩涡震荡90s后,于60℃水浴锅中静置分层,室温冷却后取上层液1mL于10mL离心管中,再加入4mL异辛烷及1mL醋酸铜显色剂漩涡震荡90s,静置分层后取上层有机相,在波长714nm处测定吸光度。空白实验平行进行,区别仅在于没有添加减肥组合物,其他操作相同。胰脂肪酶抑制率的计算公式如下:
胰脂肪酶抑制率(%)=(1-Ab/Aa)×100%
其中,Ab为空白实验的吸光度;Aa为添加减肥组合物后测得的吸光度。具体的测试结果如下表所示。
实施例1 | 实施例2 | 实施例3 | |
抑制率% | 57.77±2.14 | 51.74±1.15 | 50.01±1.11 |
实验例2
该减肥组合物中寡肽抑制胰脂肪的抑制机理测定步骤如下:
油酸标准曲线:配制一系列不同浓度的油酸/苯溶液(0,3.2mg/mL,6.4mg/mL,12.8mg/mL,19.2mg/mL,25.6mg/mL,32mg/mL),分别取4mL于锥形瓶中,加入1mL乙酸铜(5%)显色液,磁力搅拌5min,8000rpm离心10min后,取上层有机相在714nm下测定吸光度,以未加入油酸的空白溶液作为参照。以油酸浓度为横坐标,吸光度值为纵坐标,得到油酸标准曲线。
将实施例1制得的减肥组合物分别配置成氨基酸序列为Ala-Pro-Tyr-Arg的寡肽含量为0mg/mL,5mg/mL和10mg/mL的溶液;分别加入5个不同浓度的白色橄榄油底物乳化液,分别于37℃下反应20min,根据油酸标准曲线得到相应的反应产物(脂肪酸)的含量(C:mg/mL),进而求出各反应速度,结果如图2所示。反应速度V=C/t,其中C指的是反应之后脂肪酸的含量,t指的是寡肽溶液中加入白色橄榄油底物乳化液后的反应时间(min)。由图2可知,该抑制类型为非竞争性抑制。具体数值如下表所示。
表3结果
实验例3
将实施例2制得的减肥组合物配置成氨基酸序列为Ala-Pro-Tyr-Arg的寡肽含量为1mg/mL的溶液,平均分为7份,然后分别用0.1M的盐酸或氢氧化钠溶液调节至不同的pH值:3,5,7,9,10,11和12,然后在25℃保温60min后,分别将上述溶液调节pH值至7.0,之后按照实验例1的测试方法分别测其胰脂肪酶抑制活性。
胰脂肪酶抑制活性保留率的计算公式如下:
胰脂肪酶抑制活性保留率%=Ip/Ic×100%;
其中,Ic是pH为7时的胰脂肪酶抑制率,Ip为其它pH的胰脂肪酶抑制率。
具体的实验结果见图3,图3中的“工”字代表标准差,具体数值如下表所示。由图3可知,pH值对包含APYR寡肽的减肥组合物的胰脂肪酶抑制活性具有显著的影响。当溶液pH>10时,随着pH的升高,其抑制活性保留率显著降低。这可能是因为寡肽在强碱性条件下,其构象易发生改变,从而导致活性降低。在中性和偏碱性范围内,胰脂肪酶抑制活性变化不显著,活性保持率均在95%以上。说明该减肥组合物在中性和弱碱性条件下可以稳定存在,能保持较高的体外胰脂肪酶抑制活性。当pH值低于5.0或者高于11.0时,胰脂肪酶抑制活性均存在一定程度的损失。
表4胰脂肪酶抑制活性保留率
实验例4
采用如下化学合成的方法制备Ala-Pro-Tyr-Arg的寡肽:
(1)称取1g聚苯乙烯树脂放入反应柱中,加入DCM(二氯甲烷)溶胀30min,然后抽掉DCM,加入2g的序列中第一个氨基酸(Ala),2g的DIEA(二异丙基乙胺),5mL的DMF(二甲基甲酰胺)和5mL的DCM,向反应体系中鼓氮气(0.025立方米/min),从体系中开始至有鼓泡计时反应60min。然后加入5个当量甲醇,反应30min,抽掉反应液,使得Glu中的羧基负载在树脂上,然后用DMF(5mL)和MeOH(5mL)的分别冲洗树脂;
(2)反应柱中加入2g序列中的第二个氨基酸(Pro,且该Pro的氨基是由Fmoc保护的),2g HBTU(苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐)及5mL DIEA,向反应体系中以鼓氮气(0.025立方米/min),从体系中开始至有鼓泡计时反应30min,洗掉液体,加入5mL的脱帽液去除Fmoc(9-芴甲氧羰基)保护基,然后用DMF(5mL)和MeOH(5mL)的分别冲洗树脂,茚三酮检测氨基已脱保护后,可进行下一步;
(3)依步骤2的方法依次加入序列中不同氨基酸(氨基均由Fmoc保护)并进行各种修饰;
(4)将树脂用氮气吹干后从反应柱中取下,倒入烧瓶中,然后往烧瓶中加的切割液(所述切割液的组成是95wt%三氯乙酸,2wt%乙二硫醇,2wt%三异丙基硅烷和1wt%水),震荡,滤掉树脂得滤液;其中,切割液和树脂比例为10mL:1g;
(5)然后向滤液中加入10mL乙醚(有沉淀产生),离心,将沉淀用乙醚清洗,即得Ala-Pro-Tyr-Arg寡肽的粗产物;
(6)利用高效液相色谱分离上述的寡肽粗产物至纯度不小于98%;
(7)将高效液相色谱分离得到的纯度不小于98%的寡肽溶液放入冻干机进行浓缩,冻干得白色粉末状Ala-Pro-Tyr-Arg的寡肽。
将上述纯化得到的Ala-Pro-Tyr-Arg的寡肽,分别配制成不同浓度的水溶液,然后均按照实验例1中的方法测定其不同浓度下的胰脂肪抑制率;并以浓度作为横坐标,胰脂肪酶的抑制率为纵坐标,制作曲线,通过该曲线计算半抑制的抑制浓度IC50。结果下表所示。
表5实验结果
由上表中的数据可知,随着寡肽浓度的增加,胰脂肪酶抑制率增加,且其半数抑制率也就是抑制率为50%的浓度为350.41±0.55μg/mL。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
SEQUENCE LISTING
<110> 完美(广东)日用品有限公司
<120> 一种寡肽、减肥组合物及制备方法和应用
<130> HA202001476
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 4
<212> PRT
<213> 人工序列
<400> 1
Ala Pro Tyr Arg
1
Claims (9)
1.一种寡肽,其特征在于,为如下的氨基酸序列:Ala-Pro-Tyr-Arg。
2.一种减肥组合物,其特征在于,包含权利要求1所述的寡肽。
3.根据权利要求2所述的减肥组合物,其特征在于,所述减肥组合物中寡肽的含量为0.4-2.5g/100g。
4.根据权利要求2或3所述的减肥组合物,其特征在于,所述减肥组合物为膳食补充剂。
5.权利要求2所述的减肥组合物的制备方法,其特征在于,包括如下步骤:
将沙棘籽粉碎后加水,调节pH为5.0-7.0,酶解,灭酶,取上清液,即得所述减肥组合物;
酶解时采用胰酶;
粉碎后沙棘籽与酶的质量比为100:1.0-2.0;
酶解的温度为25-60℃,时间为15-24h;
粉碎后沙棘籽与水的质量比为1:12-15。
6.权利要求1所述寡肽的提纯方法,其特征在于,包括如下步骤:
将权利要求2-4任一项所述的减肥组合物或权利要求5所述的减肥组合物的制备方法制得的减肥组合物依次经超滤、阳离子交换树脂,透析,色谱柱分离,即得所述寡肽。
7.根据权利要求6所述的寡肽的提纯方法,其特征在于,超滤时收集分子量小于3kDa的滤液。
8.权利要求1所述的寡肽或权利要求6或7所述的寡肽的提纯方法提取的寡肽或权利要求2-4任一项所述的减肥组合物或权利要求5所述的减肥组合物的制备方法制得的减肥组合物在非疾病治疗目的抑制胰脂肪酶活性中的应用。
9.权利要求1所述的寡肽或权利要求6或7所述的寡肽的提纯方法提取的寡肽或权利要求2-4任一项所述的减肥组合物或权利要求5所述的减肥组合物的制备方法制得的减肥组合物在制备减肥类食品、药品或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010571191.2A CN111732629B (zh) | 2020-06-19 | 2020-06-19 | 一种寡肽、减肥组合物及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010571191.2A CN111732629B (zh) | 2020-06-19 | 2020-06-19 | 一种寡肽、减肥组合物及制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111732629A CN111732629A (zh) | 2020-10-02 |
CN111732629B true CN111732629B (zh) | 2022-05-03 |
Family
ID=72651978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010571191.2A Active CN111732629B (zh) | 2020-06-19 | 2020-06-19 | 一种寡肽、减肥组合物及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111732629B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115925799B (zh) * | 2022-12-28 | 2023-08-29 | 中国农业大学 | 一种具有降脂活性的小米寡肽 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
EP4316597A2 (en) * | 2017-07-07 | 2024-02-07 | immatics biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
-
2020
- 2020-06-19 CN CN202010571191.2A patent/CN111732629B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111732629A (zh) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
He et al. | Preparation and functional evaluation of oligopeptide-enriched hydrolysate from shrimp (Acetes chinensis) treated with crude protease from Bacillus sp. SM98011 | |
Brady et al. | Identification of the dietary lectin, wheat germ agglutinin, in human intestinal contents | |
Woodard et al. | Toxicity of alkali-treated soyprotein in rats | |
US20120302731A1 (en) | Protein hydrolysate, polypeptide solution and polypeptide, preparation method and use thereof | |
WO2016138783A1 (zh) | 一种具有降尿酸活性的秋刀鱼美拉德肽及其制法和应用 | |
CN101744093B (zh) | 一种茶叶蛋白多肽及其制备方法和用途 | |
CN104263789B (zh) | 体外模拟胃肠消化制备绿鳍马面鲀鱼皮抗氧化肽液的方法 | |
CN111662361B (zh) | 一种寡肽、减肥组合物及制备方法和应用 | |
CN111732629B (zh) | 一种寡肽、减肥组合物及制备方法和应用 | |
CN110563808A (zh) | 一种南极磷虾抗氧化寡肽及其制备方法 | |
CN108794570B (zh) | 一种含苯丙氨酸的黄嘌呤氧化酶抑制剂及其用途 | |
Wang et al. | Extraction and characterization of anti-oxidative polysaccharide–protein complexes from Corbicula fluminea through three-phase partitioning | |
US10434148B2 (en) | Preparation method of albumin peptide combination having the action of inhibiting the proliferation of cancer cells | |
Pontieri et al. | Comparison of extraction methods for isolating kafirin protein from food grade sorghum flour | |
Wen et al. | A review on selenium-enriched proteins: preparation, purification, identification, bioavailability, bioactivities and application | |
Qian et al. | Plastein reaction enhanced bile-acid binding capacity of soybean protein hydrolysates and whey protein hydrolysates | |
CN109680027A (zh) | 一种灰树花小肽铁螯合物及其制备方法和应用 | |
CA3071190C (en) | Spent turmeric - methods and compositions thereof | |
CN109486886B (zh) | 一种玉米低聚肽硒及其制备方法和应用 | |
AU2008100719A4 (en) | Papaya resin for gluten digestion and uses thereof | |
CN115109817B (zh) | 一种具有抗氧化及免疫活性的苦杏仁肽及其制备方法和用途 | |
Yoo et al. | Calcium solubilization ability and anti-inflammatory effects of hydrolyzed casein | |
CN110256319B (zh) | 一种从酶解的玉米蛋白粉中提取玉米黄素的方法 | |
Lee et al. | Lysophosphatidylcholine identified as channel-associated phospholipid of maize starch granules | |
Laosam et al. | Molecular structures and in vitro bioactivities of enzymatically produced porcine placenta peptides fractionated by ultrafiltration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |